tetano
Editor, Senior Moderator
BMC Nephrol
. 2022 Sep 21;23(1):317.
doi: 10.1186/s12882-022-02940-2.
SARS-CoV-2 in dialysis patients and the impact of vaccination
Louise Rachel Moore[SUP] 1 2 [/SUP], Noor Al-Jaddou[SUP] 3 [/SUP], Harsha Wodeyar[SUP] 3 [/SUP], Asheesh Sharma[SUP] 3 [/SUP], Michael Schulz[SUP] 3 [/SUP], Anirudh Rao[SUP] 3 [/SUP], Kottarathil Abraham[SUP] 3 [/SUP]
Affiliations
Abstract
Background: In centre haemodialysis (ICHD) patients have been identified as high risk of contracting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection due to frequent healthcare contact and poor innate and adaptive immunity. Our ICHD patients were offered immunisation from January 2021. We aimed to assess outcomes following SARS-CoV-2 infection and report on the effect of vaccination in our ICHD patients.
Methods: Demographics, SARS-CoV-2 status, hospitalisation, mortality and vaccination status were analysed. From 11[SUP]th[/SUP] March 2020 to 31[SUP]st[/SUP] March 2021, 662 ICHD patients were included in the study and these patients were then followed up until 31[SUP]st[/SUP] August 2021.
Results: SARS-CoV-2 infection occurred in 28.4% with 51.1% of them requiring hospitalisation in contrast to community infection rates of 13.9% and hospitalisation of 9.0%. 28-day mortality was 19.2% in comparison to 1.9% of the community. Mortality increased to 34.0% over the study period. Mortality over the study period was 1.8 times in infected patients (HR 1.81 (1.32-2.49) P < 0.001) despite adjustment for age, gender and ethnicity. 91.3% of ICHD patients have now received both doses of SARS-CoV-2 vaccinations.
Conclusions: ICHD patients are at increased risk of acquiring SARS-CoV-2, with increased rates of hospitalisation and mortality. The increased mortality extends well beyond the 28 days post-infection and persists in those who have recovered. Peaks and troughs in infection rates mirrored community trends. Preliminary data indicates that the SARS-CoV-2 vaccination provides protection to ICHD patients, with ICHD case rates now comparable to that of the local population.
Keywords: Dialysis patients; Efficacy; SARS-CoV-2; Vaccination.
. 2022 Sep 21;23(1):317.
doi: 10.1186/s12882-022-02940-2.
SARS-CoV-2 in dialysis patients and the impact of vaccination
Louise Rachel Moore[SUP] 1 2 [/SUP], Noor Al-Jaddou[SUP] 3 [/SUP], Harsha Wodeyar[SUP] 3 [/SUP], Asheesh Sharma[SUP] 3 [/SUP], Michael Schulz[SUP] 3 [/SUP], Anirudh Rao[SUP] 3 [/SUP], Kottarathil Abraham[SUP] 3 [/SUP]
Affiliations
- PMID: 36131241
- DOI: 10.1186/s12882-022-02940-2
Abstract
Background: In centre haemodialysis (ICHD) patients have been identified as high risk of contracting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection due to frequent healthcare contact and poor innate and adaptive immunity. Our ICHD patients were offered immunisation from January 2021. We aimed to assess outcomes following SARS-CoV-2 infection and report on the effect of vaccination in our ICHD patients.
Methods: Demographics, SARS-CoV-2 status, hospitalisation, mortality and vaccination status were analysed. From 11[SUP]th[/SUP] March 2020 to 31[SUP]st[/SUP] March 2021, 662 ICHD patients were included in the study and these patients were then followed up until 31[SUP]st[/SUP] August 2021.
Results: SARS-CoV-2 infection occurred in 28.4% with 51.1% of them requiring hospitalisation in contrast to community infection rates of 13.9% and hospitalisation of 9.0%. 28-day mortality was 19.2% in comparison to 1.9% of the community. Mortality increased to 34.0% over the study period. Mortality over the study period was 1.8 times in infected patients (HR 1.81 (1.32-2.49) P < 0.001) despite adjustment for age, gender and ethnicity. 91.3% of ICHD patients have now received both doses of SARS-CoV-2 vaccinations.
Conclusions: ICHD patients are at increased risk of acquiring SARS-CoV-2, with increased rates of hospitalisation and mortality. The increased mortality extends well beyond the 28 days post-infection and persists in those who have recovered. Peaks and troughs in infection rates mirrored community trends. Preliminary data indicates that the SARS-CoV-2 vaccination provides protection to ICHD patients, with ICHD case rates now comparable to that of the local population.
Keywords: Dialysis patients; Efficacy; SARS-CoV-2; Vaccination.